Historical Press Releases

2013

Soligenix Submits BARDA Contract Proposal for Development of OrbeShieldTM in GI ARS

Princeton, NJ – February 20, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract...

Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – February 26, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year...

Soligenix Announces Significant Progress with ThermoVax™ Towards the Development of Heat Stable Vaccines

Princeton, NJ – March 19, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of...

Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis

Princeton, NJ – March 27, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration...

Soligenix to Present at World Vaccine Congress & Expo

Princeton, NJ – April 16, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products for serious inflammatory...

Show per page